148 related articles for article (PubMed ID: 1970265)
1. Carvedilol increases the systemic bioavailability of oral digoxin.
De Mey C; Brendel E; Enterling D
Br J Clin Pharmacol; 1990 Apr; 29(4):486-90. PubMed ID: 1970265
[TBL] [Abstract][Full Text] [Related]
2. Effects of long-term oral carvedilol on the steady-state pharmacokinetics of oral digoxin in patients with mild to moderate hypertension.
Wermeling DP; Field CJ; Smith DA; Chandler MH; Clifton GD; Boyle DA
Pharmacotherapy; 1994; 14(5):600-6. PubMed ID: 7997394
[TBL] [Abstract][Full Text] [Related]
3. Carvedilol increases ciclosporin bioavailability by inhibiting P-glycoprotein-mediated transport.
Amioka K; Kuzuya T; Kushihara H; Ejiri M; Nitta A; Nabeshima T
J Pharm Pharmacol; 2007 Oct; 59(10):1383-7. PubMed ID: 17910813
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
[TBL] [Abstract][Full Text] [Related]
5. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein.
Westphal K; Weinbrenner A; Giessmann T; Stuhr M; Franke G; Zschiesche M; Oertel R; Terhaag B; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2000 Jul; 68(1):6-12. PubMed ID: 10945310
[TBL] [Abstract][Full Text] [Related]
6. Should pharmacotherapy of digoxin be reviewed in male patients with heart failure in the case of association with carvedilol?
Souza FC; Neri JS; Marques EB; Barros RB; Scaramello CB
Int J Cardiol; 2015 Jul; 191():4-6. PubMed ID: 25957928
[No Abstract] [Full Text] [Related]
7. The contractility enhancing effect of the calcium sensitiser levosimendan is not attenuated by carvedilol in healthy subjects.
Lehtonen L; Sundberg S
Eur J Clin Pharmacol; 2002 Oct; 58(7):449-52. PubMed ID: 12389066
[TBL] [Abstract][Full Text] [Related]
8. Dose-effect and pharmacokinetic-pharmacodynamic relationships of the beta 1-adrenergic receptor blocking properties of various doses of carvedilol in healthy humans.
de Mey C; Breithaupt K; Schloos J; Neugebauer G; Palm D; Belz GG
Clin Pharmacol Ther; 1994 Mar; 55(3):329-37. PubMed ID: 7908256
[TBL] [Abstract][Full Text] [Related]
9. Effects of cilostazol on the pharmacokinetics of carvedilol after oral and intravenous administration in rats.
Lim TH; Cho YA; Choi DH
J Physiol Pharmacol; 2015 Aug; 66(4):591-7. PubMed ID: 26348083
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs.
Beddies G; Fox PR; Papich MD; Kanikanti VR; Krebber R; Keene BW
Am J Vet Res; 2008 Dec; 69(12):1659-63. PubMed ID: 19046015
[TBL] [Abstract][Full Text] [Related]
11. Acute effects of a single oral dose of carvedilol on cardiac sympathovagal balance in man.
Haseroth K; Löffler P; Janson CP; Kropff S; Schmidt BM; Feuring M; Christ M; Wehling M
Int J Clin Pharmacol Ther; 2001 Jul; 39(7):315-21. PubMed ID: 11471776
[TBL] [Abstract][Full Text] [Related]
12. Stereoselective effects of (R)- and (S)-carvedilol in humans.
Stoschitzky K; Koshucharova G; Lercher P; Maier R; Sakotnik A; Klein W; Liebmann PM; Lindner W
Chirality; 2001 Jul; 13(7):342-6. PubMed ID: 11400186
[TBL] [Abstract][Full Text] [Related]
13. An alternative hypothesis to involvement of intestinal P-glycoprotein as the cause for digoxin oral bioavailability enhancement by talinolol.
Chiou WL; Ma C; Chung SM; Wu TC
Clin Pharmacol Ther; 2001 Jan; 69(1):79-81. PubMed ID: 11180042
[No Abstract] [Full Text] [Related]
14. Acute cardiovascular effects and pharmacokinetics of carvedilol in healthy dogs.
Sawangkoon S; Miyamoto M; Nakayama T; Hamlin RL
Am J Vet Res; 2000 Jan; 61(1):57-60. PubMed ID: 10630779
[TBL] [Abstract][Full Text] [Related]
15. Investigation of possible pharmacokinetic and pharmacodynamic interactions between epanolol and digoxin.
Lefebvre RA; Bogaert MG; Duprez D
Eur J Clin Pharmacol; 1990; 38(5):505-7. PubMed ID: 1974206
[TBL] [Abstract][Full Text] [Related]
16. Hemodynamic effects of orally administered carvedilol in healthy conscious dogs.
Abbott JA; Broadstone RV; Ward DL; Pyle RL
Am J Vet Res; 2005 Apr; 66(4):637-41. PubMed ID: 15900944
[TBL] [Abstract][Full Text] [Related]
17. Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein.
Bachmakov I; Werner U; Endress B; Auge D; Fromm MF
Fundam Clin Pharmacol; 2006 Jun; 20(3):273-82. PubMed ID: 16671962
[TBL] [Abstract][Full Text] [Related]
18. Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound.
Neugebauer G; Akpan W; Kaufmann B; Reiff K
Eur J Clin Pharmacol; 1990; 38 Suppl 2():S108-11. PubMed ID: 1974498
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogs.
Arsenault WG; Boothe DM; Gordon SG; Miller MW; Chalkley JR; Petrikovics I
Am J Vet Res; 2005 Dec; 66(12):2172-6. PubMed ID: 16379664
[TBL] [Abstract][Full Text] [Related]
20. Effects of carvedilol on the metabolic, hemodynamic, and electrocardiographic responses to increased plasma epinephrine in normal subjects.
Hansen O; Johansson BW; Nilsson-Ehle P; Eklund B; Ohlsson I; Palenmark E; Pauler AM; Svensson K
J Cardiovasc Pharmacol; 1994 Dec; 24(6):853-9. PubMed ID: 7898065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
